45 results about "Ophthalmic drug" patented technology

The invention relates to the field of drug delivery devices. More particularly, the invention relates to implantable, refillable drug delivery devices which provide for drug delivery over sustained time periods. The present invention has particular application for ophthalmic drug delivery applications.

Methods and devices measure eye blinks and tear film lipid and aqueous layer thickness before and following ophthalmic formula application onto the ocular surface, especially wherein the ophthalmic formula is an artificial tear. The methods and devices are suitable for dry eye diagnosis. The methods and devices are suitable for use to evaluate ophthalmic formula effects on the tear film and to use such information to diagnose ophthalmic formula treatment of ocular disease conditions such as dry eye in the absence of contact lens wear or post-surgical eye drop treatment and diagnosis. The methods and devices are also suitable for use in the optimization of ophthalmic drug dosage forms and sustained drug release.

Devices, systems and techniques for delivering drugs to an ocular tissue are described. In at least some embodiments, a terminal component (e.g., a needle or open end of a catheter) is implanted in an ocular tissue and used to deliver one or more drugs. The delivered drugs may come from a source which is also implanted, or may be introduced from an external source (e.g., via a port). Both solid and liquid drug formulations can be used. Ocular implants can alternatively include a thin film coating that releases a drug into an ocular tissue.

A drug delivery system comprising a contact lens having dispersed therein as nanoparticles having a particle size less than about 50 nm, an ophthalmic drug nanoencapsulated in a material from which said ophthalmic drug is capable of diffusion into and migration through said contact lens and into the post-lens tear film when said contact lens is placed on the eye.

Methods and devices measure eye blinks and tear film lipid and aqueous layer thickness before and following ophthalmic formula application onto the ocular surface, especially wherein the ophthalmic formula is an artificial tear. The methods and devices are suitable for dry eye diagnosis. The methods and devices are suitable for use to evaluate ophthalmic formula effects on the tear film and to use such information to diagnose ophthalmic formula treatment of ocular disease conditions such as dry eye in the absence of contact lens wear or post-surgical eye drop treatment and diagnosis. The methods and devices are also suitable for use in the optimization of ophthalmic drug dosage forms and sustained drug release.

A drug delivery system comprising a contact lens having dispersed therein as nanoparticles having a particle size less than about 200 nm, an ophthalmic drug nanoencapsulated in a material from which said ophthalmic drug is capable of diffusion into and migration through said contact lens and into the post-lens tear film when said contact lens is placed on the eye.

The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.

An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery system and contains an active pharmaceutical agent, a lubricant, etc. In a second embodiment the ocular device can be constructed in such a manner to treat a wide variety of ocular conditions and diseases.

A bicontinuous microemulsion of water, a monomer, and a surfactant copolymerizable with the monomer is polymerized to form a transparent and porous polymer defining interconnected pores. The pores may have a pore diameter in the range of 10 to 100 mm. The microemulsion may further include a drug such that, when the polymer is formed, the drug is dispersed in one or both of the polymer and the pores and is releasable therefrom when the polymer is in contact with a liquid. The drug may be an ophthalmic drug and the polyer can be used to form drug delivery devices, such as contact lenses and artificial corneas.

A dispensing tip apparatus for an eye drop dispenser to administer topical ophthalmic solutions is described. The apparatus integrates an ophthalmic solution-dispensing tip with an optical gauging assembly. The tip provides continuous visual feedback about it orientation and relationship to the eye. The dispensing tip when attached to any standard topical ophthalmic solution dispensing bottle or reservoir enables the user to view a target, visually align the dispenser tip, and administer an eye drop with precision. There is also a visual feedback by which the dispenser tip is prevented from gaining too close proximity and contacting the eye, thus preventing contamination of the medication and its dispenser. The visual feedback can also contain textual or graphic information that serves as a promotional advertisement.

The invention relates to artificial tear containing trehalose and the preparation and application method, which pertains to the technical field of pharmaceutical manufacture. The main component of the invention is the trehalose, the basic composition of the artificial tear is the trehalose, simulating mucin protein and conventional ophthalmic pharmaceutical excipients; the weight ratio of the three is that 0.3 to 97 percent trehalose, 0.3 to 97 percent simulating mucin protein and 2 to 98 percent conventional ophthalmic pharmaceutical excipients. The pH and the osmotic pressure of the artificial tear of the invention are equivalent to physiologic tear, the invention contains rich electrolyte ions, the type and the content of the ions are equivalent to the physiologic tear, and the invention can be used in the treatment of dry eye syndrome and the adjuvant treatment of diseases which are caused by other dry eye syndromes. At the same time, the invention can be used as the drug delivery system of various ophthalmic drugs.

The invention relates to an application of an HMGCoA reductase inhibitor in preparation of a medicine used for treating xerophthalmia and belongs to the field of medicines. The inventor finds that a frequently-used lipid regulation medicine, the HMGCoA reductase inhibitor, can obviously prolong SIT time and BUT time and obviously reduce an FLS score when being used for treating the xerophthalmia, and the HMGCoA reductase inhibitor is better than ciclosporin or artificial tears in the aspect of improving the indexes, wherein simvastatin and lovastatin have the best treatment effect. The HMGCoA reductase inhibitor also can be prepared into oral preparation used for treatment or adjuvant therapy of the xerophthalmia. The HMGCoA reductase inhibitor has a definite curative effect and less toxic and side effects, compliance of a patient is high, and clinical ophthalmic drugs are further enriched.

It is described a gel composed of a mixture of a polymer which forms a gel, a buffer; a saccharide and one or more active ingredients useful for treating diseases of the eyes.

The invention relates to an ophthalmic drug combination and preparation and application methods thereof. The ophthalmic drug combination comprises N-(2)-L-alanyl-L-glutamine which is suspended or dissolved inside eye-acceptable isotonic solution. The ophthalmic drug combination is low in irritation, good in stability and high in safety.

The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.

The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective. In addition, utilizing the nonaqueous oil delivery system as eye drops produces no ocular sensation of burning, stinging or excessive tearing that is commonly associated with the commercially available aqueous eye drops. This very dilute ophthalmic drug preparation has a greatly reduced systemic toxicity potential as compared to the commercially used aqueous ophthalmic drops. The vehicle includes castor oil, corn oil, glycerol, mineral oil USP, vegetable oil, white petrolatum USP, and mixtures, there of. The ophthalmic class of drugs includes antimicrobials, miotics, mydriatics, mydriatic-cycloplegics, mydriatic-cycloplegic reversal agents and topical anesthetics.

The present invention relates to a drug release device for the human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates implanting the device on an outer surface of the sclera, below the inferior oblique muscle, and deploying the pharmaceutically active agent to the macula above. Also disclosed is a method of delivering a pharmaceutically active agent to the back of the human eye.

The invention provides an in-situ gel containing cyclosporin micelles as a sustained release ophthalmic drug delivery system. The in-situ gel contains 0.01 wt% to 5 wt% of an aqueous ophthalmic formulation of cyclosporin present in the form of a micelle with the particle size of no greater than 20 nm.

The invention relates to a novel antithrombotic polymer nano-drug. The novel antithrombotic polymer nano-drug is prepared by connecting a hydrophobic antithrombotic substance with a hydrophilic antithrombotic substance by means of a simple chemical reaction; the novel antithrombotic polymer nano-drug can be separately used as a polymer nano-drug, and can be also prepared into a polymer nano-drug composition by being physically coated with other pharmaceutically active or pharmacologically active molecules so as to improve the antithrombotic activity of the pharmaceutically active or pharmacologically active molecules. The antithrombotic polymer nano-drug not only improves the water solubility and stability of the hydrophobic antithrombotic substance, prolongs the action time of the hydrophobic antithrombotic substance and increases the concentration of the drug reaching the part with thrombus, but also reduces the bleeding risk of heparin of the hydrophilic antithrombotic substance and derivatives thereof and realizes the cooperative utilization of two different action mechanisms, thus giving play to higher antithrombotic activity. By adding corresponding medical auxiliary materials, the antithrombotic polymer nano-drug and a composition thereof can be prepared into corresponding preparations used for injection, oral administration or ophthalmic drug delivery. The preparation method of the novel antithrombotic polymer nano-drug is simple and lower in cost, thus being suitable for large-scale continuous production.

The invention relates to a vaccine for preventing brucellosis by means of ophthalmic drug delivery. Through adoption of the vaccine for preventing brucellosis by means of ophthalmic drug delivery, the problems of continuous production of antibodies by immune cows, abortion of pregnant cows and bacterium excretion in adult cow milk due to conventional subcutaneous injection of a bacterium burgeri vaccine are solved.

An ophthalmic drug delivery device comprises a shell, a pushing device and an injection device, the pushing device and the injection device are installed on the shell, a speed reducing mechanism is connected between the pushing device and the injection device, and the pushing device pushes the injection device after being decelerated through the speed reducing mechanism. The advancing distance of the injection device is smaller than the propelling distance of the pushing device, so that the dosage error of eye administration is reduced, and the accuracy of eye micro-administration is improved.